Suppr超能文献

接受血液透析与腹膜透析的终末期肾病患者的生存率比较。

Comparison of survival in patients with end-stage renal disease receiving hemodialysis versus peritoneal dialysis.

作者信息

Beladi Mousavi Seyed Seifollah, Hayati Fatemeh, Valavi Ehsan, Rekabi Fazlollah, Mousavi Marzieh Beladi

机构信息

Department of Pediatric, Jundishapour University of Medical Sciences, Ahvaz, Iran.

出版信息

Saudi J Kidney Dis Transpl. 2015 Mar;26(2):392-7. doi: 10.4103/1319-2442.152559.

Abstract

Although the life expectancy of patients with end-stage renal disease (ESRD) has improved in recent years, it is still far below that of the general population. In this retrospective study, we compared the survival of patients with ESRD receiving hemodialysis (HD) versus those on peritoneal dialysis (PD). The study was conducted on patients referred to the HD and PD centers of the Emam Khomini Hospital and the Aboozar Children's Hospital from January 2007 to May 2012 in Ahvaz, Iran. All ESRD patients on maintenance HD or PD for more than two months were included in the study. The survival was estimated by the Kaplan-Meier method and the differences between HD and PD patients were tested by the log-rank test. Overall, 239 patients, 148 patients on HD (61.92%) and 91 patients on continuous ambulatory PD (CAPD) (38.55%) with mean age of 54.1 ± 17 years were enrolled in the study. Regardless of the causes of ESRD and type of renal replacement therapy (RRT), one-, two- and three-year survival of patients was 65%, 51% and 35%, respectively. There was no significant difference between type of RRT in one- (P-value = 0.737), two- (P-value = 0.534) and three- (P-value = 0.867) year survival. There was also no significant difference between diabetic and non-diabetic patients under HD and CAPD in the one-, two- and three-year survival. Although the three-year survival of diabetic patients under CAPD was lower than that of non-diabetic patients (13% vs. 34%), it was not statistically significant (P-value = 0.50). According to the results of the current study, there is no survival advantage of PD during the first years of initiation of dialysis, and the one-, two- and three-year survival of HD and PD patients is also similar.

摘要

尽管近年来终末期肾病(ESRD)患者的预期寿命有所提高,但仍远低于普通人群。在这项回顾性研究中,我们比较了接受血液透析(HD)的ESRD患者与接受腹膜透析(PD)的患者的生存率。该研究针对2007年1月至2012年5月转诊至伊朗阿瓦士伊玛目霍梅尼医院和阿博扎尔儿童医院HD和PD中心的患者进行。所有接受维持性HD或PD超过两个月的ESRD患者均纳入研究。采用Kaplan-Meier方法估计生存率,并通过对数秩检验检验HD和PD患者之间的差异。总体而言,239例患者纳入研究,其中148例接受HD(61.92%),91例接受持续性非卧床腹膜透析(CAPD)(38.55%),平均年龄为54.1±17岁。无论ESRD的病因和肾脏替代治疗(RRT)的类型如何,患者的1年、2年和3年生存率分别为65%、51%和35%。RRT类型在1年(P值=0.737)、2年(P值=0.534)和3年(P值=0.867)生存率方面无显著差异。HD和CAPD下糖尿病患者和非糖尿病患者在1年、2年和3年生存率方面也无显著差异。尽管CAPD下糖尿病患者的3年生存率低于非糖尿病患者(13%对34%),但差异无统计学意义(P值=0.50)。根据本研究结果,在透析开始的最初几年中,PD没有生存优势,HD和PD患者的1年、2年和3年生存率也相似。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验